Rare Cancer News & Clinical Trials » Trial

Process Optimization of Preoperative Biliary Drainage in Hilar Cholangiocarcinoma Patients

Posted: May 17th, 2018, 2:00pm GMT

Conditions: Jaundice, Obstructive; Klatskin Tumor
Interventions: Procedure: PTBD group; Procedure: ENBD group; Procedure: EBS group
Sponsor: Shanghai Zhongshan Hospital
Not yet recruiting

A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma

Posted: May 10th, 2018, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Intervention: Drug: Apatinib
Sponsors: The First Affiliated Hospital of Zhengzhou University; Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Precise Treatment System of Biliary Malignancies Based on Special Disease Database

Posted: April 17th, 2018, 2:00pm GMT

Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma; Biliary System Disorder
Intervention:
Sponsors: Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; First Affiliated Hospital Xi'an Jiaotong University; The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Dalian Medical University; Shanghai Zhongshan Hospital; Southwest Hospital, China; Tianjin Medical University Cancer Institute and Hospital; Sun Yat-sen University; Afﬁliated Hospital of North Sichuan Medical College; The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School; Second Affiliated Hospital, School of Medicine, Zhejiang University; Eastern Hepatobiliary Surgery Hospital
Recruiting

EUS Evaluation of CBD Diameter in Malignant Obstructive Jaundice

Posted: April 11th, 2018, 2:00pm GMT

Conditions: Pancreatic Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Ampulla of Vater Cancer; Jaundice, Obstructive
Intervention: Diagnostic Test: Endoscopic ultrasound
Sponsors: Clinical Hospital Colentina; Catholic University, Italy
Recruiting

SHR-1210 in Combination With GEMOX in Patients With Advanced BTC

Posted: April 3rd, 2018, 2:00pm GMT

Conditions: Biliary Tract Cancer; Cholangiocarcinoma
Intervention: Drug: SHR-1210+GEMOX
Sponsors: The First Affiliated Hospital with Nanjing Medical University; Jiangsu HengRui Medicine Co., Ltd.
Recruiting

Improving Outcomes in Cancer Patients With a Nutritional and Physical Conditioning Prehabilitation Program

Posted: March 23rd, 2018, 2:00pm GMT

Conditions: Pancreatic Cancer; Liver Cancer; Bile Duct Cancer; Hepatobiliary Cancer; Surgery
Interventions: Other: Exercise; Other: Nutrition; Behavioral: Relaxation techniques
Sponsors: McGill University Health Center; Dr. Franco Carli
Recruiting

Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA Patients

Posted: March 22nd, 2018, 2:00pm GMT

Conditions: Cholangiocarcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma Non-resectable; Gallbladder Carcinoma Non-Resectable
Interventions: Biological: Durvalumab and Tremelimumab; Drug: Gemcitabine; Drug: Cisplatin
Sponsors: AIO-Studien-gGmbH; AstraZeneca
Not yet recruiting

Standardized CEUS Algorithms for Diagnosis of HCC - Prospective German Multicenter Study

Posted: January 23rd, 2018, 3:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma, Intrahepatic; Liver Cirrhosis; Liver Cancer; Liver Neoplasms; Liver Diseases
Interventions: Diagnostic Test: contrast enhanced ultrasound (CEUS); Diagnostic Test: MRI; Diagnostic Test: Histology
Sponsor: University Hospital Erlangen
Recruiting

A Study of ABC294640 (Yeliva ®) in the Treatment of Patients With Advanced Cholangiocarcinoma

Posted: December 19th, 2017, 3:00pm GMT

Conditions: Cholangiocarcinoma; Cholangiocarcinoma Non-resectable; Cholangiocarcinoma, Perihilar; Cholangiocarcinoma, Extrahepatic; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: ABC294640
Sponsor: RedHill Biopharma Limited
Recruiting

TAS102 in Combination With NAL-IRI in Advanced GI Cancers

Posted: December 11th, 2017, 3:00pm GMT

Conditions: Colorectal Adenocarcinoma; Gastric Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Stage IV Colorectal Cancer; Stage IV Gastric Cancer; Stage IV Pancreatic Cancer; Stage IVA Colorectal Cancer; Stage IVB Colorectal Cancer; Unresectable Pancreatic Carcinoma
Interventions: Drug: Nanoliposomal Irinotecan; Drug: Trifluridine and Tipiracil Hydrochloride
Sponsors: Emory University; Taiho Oncology, Inc.; Ipsen
Recruiting

A Study of CDX-1140 in Patients With Advanced Solid Tumors

Posted: November 6th, 2017, 3:00pm GMT

Conditions: Melanoma; Non-small Cell Lung Cancer; Breast Cancer; Gastric Cancer; Renal Cell Carcinoma; Ovarian Cancer; Cholangiocarcinoma; Bladder Urothelial Carcinoma; Pancreatic Adenocarcinoma; Colorectal Cancer; Esophageal Cancer; Hepatic Cancer; Head and Neck Cancer
Intervention: Drug: CDX-1140
Sponsor: Celldex Therapeutics
Recruiting

Study of GNS561 in Patients With Liver Cancer

Posted: October 20th, 2017, 2:00pm GMT

Conditions: Hepatocellular Carcinoma; Cholangiocarcinoma, Intrahepatic
Intervention: Drug: GNS561
Sponsor: Genoscience Pharma
Recruiting

A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001)

Posted: July 2nd, 2017, 2:00pm GMT

Conditions: Mesothelioma; Uveal Melanoma; Renal Cell Carcinoma; Cholangiocarcinoma
Intervention: Drug: Niraparib
Sponsors: University of Florida; Tesaro, Inc.
Not yet recruiting

Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma

Posted: April 28th, 2017, 2:00pm GMT

Condition: Hilar Cholangiocarcinoma
Intervention:
Sponsor: Zhujiang Hospital
Recruiting

Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors

Posted: April 5th, 2017, 2:00pm GMT

Condition: Neoplasms
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Anetumab ravtansine (BAY94-9343)
Sponsors: Bayer; ImmunoGen, Inc.; MorphoSys AG
Recruiting

Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer

Posted: March 30th, 2017, 2:00pm GMT

Conditions: Adenocarcinoma of the Gastroesophageal Junction; Colorectal Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Non-Resectable Cholangiocarcinoma; Non-Resectable Hepatocellular Carcinoma; Recurrent Cholangiocarcinoma; Recurrent Colorectal Carcinoma; Recurrent Gastric Carcinoma; Recurrent Hepatocellular Carcinoma; Recurrent Pancreatic Carcinoma; Recurrent Small Intestinal Carcinoma; Small Intestinal Adenocarcinoma; Stage III Colorectal Cancer; Stage III Gastric Cancer; Stage III Hepatocellular Carcinoma; Stage III Pancreatic Cancer; Stage III Small Intestinal Cancer; Stage IIIA Colorectal Cancer; Stage IIIA Gastric Cancer; Stage IIIA Hepatocellular Carcinoma; Stage IIIA Small Intestinal Cancer; Stage IIIB Colorectal Cancer; Stage IIIB Gastric Cancer; Stage IIIB Hepatocellular Carcinoma; Stage IIIB Small Intestinal Cancer; Stage IIIC Gastric Cancer; Stage IV Colorectal Cancer; Stage IV Gastric Cancer; Stage IV Hepatocellular Carcinoma; Stage IV Pancreatic Cancer; Stage IV Small Intestinal Cancer; Stage IVA Colorectal Cancer; Stage IVA Hepatocellular Carcinoma; Stage IVA Pancreatic Cancer; Stage IVB Colorectal Cancer; Stage IVB Hepatocellular Carcinoma; Stage IVB Pancreatic Cancer; Unresectable Pancreatic Carcinoma; Unresectable Small Intestinal Carcinoma
Interventions: Drug: XL888; Biological: Pembrolizumab
Sponsors: Emory University; Merck Sharp & Dohme Corp.; Exelixis
Recruiting

Percutaneous Hepatic Perfusion vs. Cisplatin/Gemcitabine in Patients With Intrahepatic Cholangiocarcinoma

Posted: March 22nd, 2017, 2:00pm GMT

Conditions: Bile Duct Cancer; Intrahepatic Cholangiocarcinoma
Interventions: Combination Product: Melphalan/HDS; Drug: Cisplatin and Gemcitabine
Sponsor: Delcath Systems Inc.
Recruiting

Permalink for 'A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors'

A Study of the Safety, Tolerability and Pharmacokinetics of ABBV-368 as a Single Agent and Combination in Subjects With Locally Advanced or Metastatic Solid Tumors

Posted: March 7th, 2017, 3:00pm GMT

Condition: Advanced or Metastatic Solid Tumors
Interventions: Drug: ABBV-368; Drug: Nivolumab
Sponsor: AbbVie
Recruiting

A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers

Posted: October 5th, 2016, 2:00pm GMT

Conditions: Gastrointestinal Cancer; Neuroendocrine Tumours; Malignant Female Reproductive System Neoplasm
Interventions: Drug: Ipilimumab; Drug: Nivolumab
Sponsors: Olivia Newton-John Cancer Research Institute; Bristol-Myers Squibb
Recruiting

Molecularly Target Therapy With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma

Posted: July 19th, 2016, 2:00pm GMT

Conditions: Cholangiocarcinoma of the Extrahepatic Bile Duct; Gallbladder Cancer
Interventions: Procedure: biological test; Drug: GEMOX; Drug: Cetuximab; Drug: Trastuzumab; Drug: Gefitinib; Drug: Lapatinib; Drug: Everolimus; Drug: Sorafenib; Drug: Crizotinib
Sponsors: Shanghai Jiao Tong University School of Medicine; Xinhua Hospital, Shanghai Jiao Tong University School of Medicine; Ruijin Hospital; RenJi Hospital; Eastern Hepatobiliary Surgery Hospital; Huashan Hospital
Recruiting

Permalink for 'Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors'

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Posted: June 23rd, 2016, 2:00pm GMT

Conditions: Neoplasms; Pancreatic Neoplasms
Interventions: Drug: LMB-100; Drug: Nab-Paclitaxel
Sponsor: National Cancer Institute (NCI)
Recruiting

Permalink for 'SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma'

SIRT Followed by CIS-GEM Chemotherapy Versus CIS-GEM Chemotherapy Alone as 1st Line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma

Posted: June 21st, 2016, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin-gemcitabine; Device: Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)
Sponsor: Sirtex Medical
Recruiting

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Posted: May 27th, 2016, 2:00pm GMT

Conditions: Solid Tumor; Breast Cancer; Colon Cancer; Cholangiocarcinoma; Soft Tissue Sarcoma
Interventions: Drug: LY3039478; Drug: Taladegib; Drug: Abemaciclib; Drug: Cisplatin; Drug: Gemcitabine; Drug: Carboplatin; Drug: LY3023414
Sponsor: Eli Lilly and Company
Recruiting

Permalink for 'A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho'

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cho

Posted: March 4th, 2016, 3:00pm GMT

Condition: Neoplasm
Intervention: Drug: Erdafitinib
Sponsor: Janssen Research & Development, LLC
Recruiting

Yttrium Y 90 Resin Microspheres Data Collection in Unresectable Liver Cancer: the RESIN Study

Posted: February 19th, 2016, 3:00pm GMT

Condition: Localized Non-Resectable Adult Liver Carcinoma
Intervention: Other: Yttrium-90 Resin Microspheres
Sponsors: Vanderbilt-Ingram Cancer Center; National Cancer Institute (NCI)
Recruiting

Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma

Posted: December 16th, 2015, 3:00pm GMT

Conditions: Biliary Carcinoma; Gall Bladder Carcinoma; Cholangiocarcinoma; Gastrointestinal Tumor
Interventions: Drug: Cisplatin; Drug: Gemcitabine; Drug: Copanlisib
Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Bayer
Recruiting

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)

Posted: December 11th, 2015, 3:00pm GMT

Condition: Advanced Cancer
Intervention: Biological: pembrolizumab
Sponsor: Merck Sharp & Dohme Corp.
Recruiting

Phase I Trial of Radiation Therapy in Patients With Liver Cancers and Impaired Liver Function

Posted: December 10th, 2015, 3:00pm GMT

Conditions: Liver Cancer; Impaired Liver Function
Interventions: Radiation: Radiation Therapy; Drug: Chemotherapy; Behavioral: Questionnaire
Sponsor: M.D. Anderson Cancer Center
Recruiting

OLAParib COmbinations

Posted: October 15th, 2015, 2:00pm GMT

Condition: Cancer
Interventions: Drug: AZD2281; Drug: AZD5363; Drug: AZD1775; Drug: AZD6738
Sponsors: Joseph Paul Eder; Dana-Farber Cancer Institute; Vanderbilt-Ingram Cancer Center
Recruiting

90Y Transarterial Radioembolization (TARE) Plus Gemcitabine and Cisplatin in Unresectable Intrahepatic Cholangiocarcinoma

Posted: July 31st, 2015, 2:00pm GMT

Condition: Intrahepatic Cholangiocarcinoma
Interventions: Device: SIR-Spheres microspheres (Yttrium-90 Microspheres); Drug: Gemcitabine; Drug: Cisplatin
Sponsor: Medical University of South Carolina
Recruiting

Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer

Posted: November 19th, 2014, 3:00pm GMT

Conditions: Breast Cancer; Colon Cancer; Extrahepatic Bile Duct Cancer; Gallbladder Cancer; Gastrointestinal Cancer; Liver and Intrahepatic Biliary Tract Cancer; Lung Cancer; Metastatic Cancer; Pancreatic Cancer; Rectal Cancer; Thyroid Gland Medullary Carcinoma; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Procedure: radionuclide imaging; Procedure: positron emission tomography; Other: laboratory biomarker analysis; Other: pharmacological study; Drug: Cu 64 anti-CEA monoclonal antibody M5A IV
Sponsors: City of Hope Medical Center; National Cancer Institute (NCI)
Recruiting

Permalink for 'Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery'

Gemcitabine Hydrochloride and Cisplatin With or Without Radiation Therapy in Treating Patients With Localized Liver Cancer That Cannot Be Removed by Surgery

Posted: July 25th, 2014, 2:00pm GMT

Conditions: Stage III Intrahepatic Cholangiocarcinoma; Stage IVA Intrahepatic Cholangiocarcinoma
Interventions: Drug: Cisplatin; Drug: Gemcitabine Hydrochloride; Radiation: Image Guided Radiation Therapy; Other: Laboratory Biomarker Analysis
Sponsors: NRG Oncology; National Cancer Institute (NCI)
Recruiting

Treatment for Bile Duct Cancer in the Liver

Posted: June 19th, 2014, 2:00pm GMT

Condition: Cholangio Carcinoma
Intervention: Drug: SIRT Yttrium-90
Sponsor: Chinese University of Hong Kong
Recruiting

CPI-613 in Treating Patients With Advanced or Metastatic Bile Duct Cancer That Cannot Be Removed By Surgery

Posted: January 11th, 2013, 3:00pm GMT

Conditions: Adult Primary Cholangiocellular Carcinoma; Advanced Adult Primary Liver Cancer; Cholangiocarcinoma of the Extrahepatic Bile Duct; Cholangiocarcinoma of the Gallbladder; Localized Unresectable Adult Primary Liver Cancer; Metastatic Extrahepatic Bile Duct Cancer; Recurrent Adult Primary Liver Cancer; Recurrent Extrahepatic Bile Duct Cancer; Unresectable Extrahepatic Bile Duct Cancer
Intervention: Drug: 6,8-bis(benzylthio)octanoic acid
Sponsors: Wake Forest University Health Sciences; National Cancer Institute (NCI)
Recruiting

Anxiety and Depression Levels in Cancer Patients After Self-Application of EFT (Emotional Freedom Techniques)

Posted: August 19th, 2008, 2:00pm GMT

Condition: Depression
Intervention: Behavioral: Lifestyle Counseling with Emotional Freedom Techniques (EFT)
Sponsor: Soul Medicine Institute
Recruiting

Rare Cancer News & Clinical Trials » Trial - Cholangiocarcinoma

Feeds

Trial - Cholangiocarcinoma (35 unread)